Biomed reports positive Phase 2 results for new oral obesity drug NA-931

Biomed Industries presented Phase 2 clinical data for NA-931—also known as Bioglutide™—at the European Association for the Study of Diabetes (EASD) meeting in Vienna. According to the company, the oral quadruple receptor agonist achieved weight loss comparable to leading injectables, while demonstrating a favorable safety profile. NA-931 is engineered to activate four metabolic hormone receptors […] The post Biomed reports positive Phase 2 results for new oral obesity drug NA-931 appeared first on Longevity.Technology.